Research programme - peptide melanocortin receptor 2 antagonists - Ipsen

Drug Profile

Research programme - peptide melanocortin receptor 2 antagonists - Ipsen

Alternative Names: ACTH receptor antagonists - Ipsen; Adrenocorticotropic hormone receptor antagonists - Ipsen; IRC 274; MC2 receptor antagonists - Ipsen

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ipsen
  • Class Peptide hormones; Peptides
  • Mechanism of Action Melanocortin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Pituitary ACTH hypersecretion

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Pituitary-ACTH-Hypersecretion in France (SC)
  • 01 Apr 2016 Pharmacodynamics data from preclinical studies in Pituitary ACTH Hypersecreation presented at the 98th Annual Meeting of the Endocrine Society (ENDO-2016)
  • 18 Aug 2015 Preclinical development is ongoing in France - Ipsen pipeline Aug 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top